TMRW is creating a proactive clinical environment that leverages deep biomarker analysis to optimise patient health and longevity. Whereas most platforms report roughly 30 blood metrics, TMRW’s system interprets around 1,700 data points, giving members far richer insight into their physiology. The company has secured an exclusive Australian partnership with U.S. epigenetic leader TruDiagnostic to offer world-class biological age testing alongside its own diagnostics. CEO Mark Britt champions “building with patients,” using data to strengthen human connection and keep members in control of their health journey. Fresh seed capital will fund expansion of TMRW’s clinical footprint and refinement of its patient experience as the business evolves beyond diagnostic tools into a comprehensive care model. Many investors are already active users, signalling early alignment between product and backers.

Total raised

$7M

Funding rounds

1

Latest round

Seed

Latest activity

Mar 2026